美国镭学会局部晚期子宫内膜癌适当使用标准执行摘要
美国镭学会妇科肿瘤专家组基于1996年至2024年的文献综述和改良Delphi法,制定了局部晚期子宫内膜腺癌管理的循证指南。指南强调辅助治疗应基于病理和分子风险因素,通常采用化疗联合放疗的联合模式,并特别指出p53异常肿瘤加用化疗至关重要,dMMR患者应考虑免疫治疗。
要点
- 辅助治疗基于病理和分子风险因素,通常采用化疗联合放疗。
- p53异常肿瘤加用化疗尤为重要,dMMR患者应考虑免疫治疗。
- IIIC2期放疗野应扩展至主动脉旁淋巴结,盆腔放疗优选IMRT。
核心结论
- 局部晚期子宫内膜癌辅助治疗选择需细致考量,未来需前瞻性研究利用分子标志物优化个性化治疗。
研究设计与样本
- 美国镭学会妇科肿瘤专家组通过共识形成搜索词、关键问题和临床病例变体,系统检索PubMed、Embase和Web of Science数据库1996年1月1日至2024年3月5日的文献,采用改良Delphi法进行两轮投票评级。
主要发现
- 最佳辅助治疗基于病理和分子风险因素,通常为化疗联合放疗以降低局部和远处复发风险,但无最佳顺序的前瞻性数据。
- PORTEC-3分子数据显示,在放疗基础上加化疗对p53异常肿瘤尤为关键。
- NRG-GY018/RUBY试验的入选标准可指导免疫治疗的适当使用,尤其应考虑用于dMMR患者。
- IIIC2期疾病放疗野应扩展至包括主动脉旁淋巴结。
- 盆腔放疗中,IMRT是首选技术以减轻毒性,有前瞻性数据支持。
关键数值与推荐
- 辅助治疗应基于病理和分子风险因素,通常包括化疗和放疗的联合模式。
- p53异常肿瘤应从放疗基础上加用化疗中获益。
- dMMR患者应考虑纳入免疫治疗。
- IIIC2期放疗野应包括主动脉旁淋巴结。
- 盆腔放疗首选IMRT技术。
临床怎么用
- 根据病理和分子风险因素制定辅助治疗方案,通常采用化疗联合放疗。
- 对p53异常肿瘤,应在放疗基础上加用化疗。
- 对dMMR患者,应考虑免疫治疗。
- IIIC2期患者放疗野应扩展至主动脉旁淋巴结。
- 盆腔放疗优先选择IMRT以减轻毒性。
局限性
- 无前瞻性数据确定化疗和放疗的最佳顺序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locally advanced endometrial cancers are heterogeneous and challenging to treat. Immunotherapy has transformed the treatment landscape. Given the complexity of tailoring adjuvant treatment recommendations, the multidisciplinary American Radium Society Gynecologic Cancer Panel created evidence-based guidelines for the management of locally advanced endometrial adenocarcinoma. METHODS AND MATERIALS: Search terms, key questions, and associated clinical case variants were formed by panel consensus. A review of the literature was conducted from January 1, 1996, to March 5, 2024, using the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines to systematically search the PubMed, Embase, and Web of Science databases to retrieve a comprehensive set of relevant articles. A well-established methodology (modified Delphi) was used by the expert panel to rate the appropriate use of procedures. RESULTS: Evidence for key questions in advanced-stage endometrial cancer was examined. Two rounds of voting were completed pertaining to the appropriateness of key management decisions for 4 clinical variants. Optimal adjuvant treatment is based on pathologic and molecular risk factors, and typically consists of combined modality therapy, with both chemotherapy and radiation, to minimize the risk of local and distant recurrence; there are no prospective data on optimal sequencing. Molecular data from PORTEC-3 highlights that adding chemotherapy to radiation is especially crucial for p53 abnormal tumors. Inclusion criteria for the NRG-GY018/RUBY trials can guide appropriateness of incorporating immunotherapy, which should be considered especially in mismatch repair-deficient (dMMR) patients. Radiation fields should be extended to include para-aortic lymph nodes in IIIC2 disease. Within pelvic radiation, intensity modulated radiation therapy is the preferred technique to mitigate toxicity as supported by prospective data. CONCLUSION: Selecting appropriate adjuvant therapies for advanced-stage endometrial cancer is nuanced. Further prospective studies harnessing molecular markers as therapeutic targets will help advance and optimize therapies for more personalized treatment of this complex disease.
引用
- McGunigal M, Sherertz T, Musa F, et al. Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Management of Locally Advanced Endometrial Cancer. Pract Radiat Oncol. 2026. PMID: 41548804. doi:10.1016/j.prro.2025.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。